Again you might be overly pessimistic - your sub issuance price could be hard to acquire but we will see - .15 cents target reached today at least.
seems having a little runway, two compounds in multiple concurrent studies and a massive opportunity for Pax and GDA application submission isn’t spooking the market at this point.
